Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, Lombardi P, Daniele G, Botticelli A, Lo Russo G, De Braud F, Marchetti P, Nuti M, Ferretti E, Farina L, Rughetti A, Petti M. Filetti M, et al. Among authors: rughetti a. Cancers (Basel). 2024 Nov 26;16(23):3955. doi: 10.3390/cancers16233955. Cancers (Basel). 2024. PMID: 39682144 Free PMC article.
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.
Zizzari IG, Napoletano C, Di Filippo A, Botticelli A, Gelibter A, Calabrò F, Rossi E, Schinzari G, Urbano F, Pomati G, Scagnoli S, Rughetti A, Caponnetto S, Marchetti P, Nuti M. Zizzari IG, et al. Among authors: rughetti a. Cancers (Basel). 2020 Sep 14;12(9):2620. doi: 10.3390/cancers12092620. Cancers (Basel). 2020. PMID: 32937860 Free PMC article.
Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients.
Cirillo A, Zizzari IG, Botticelli A, Strigari L, Rahimi H, Scagnoli S, Scirocchi F, Pernazza A, Pace A, Cerbelli B, d'Amati G, Marchetti P, Nuti M, Rughetti A, Napoletano C. Cirillo A, et al. Among authors: rughetti a. Int J Mol Sci. 2023 Apr 12;24(8):7114. doi: 10.3390/ijms24087114. Int J Mol Sci. 2023. PMID: 37108276 Free PMC article.
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients.
Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, Scagnoli S, Vernocchi P, Del Chierico F, Putignani L, Rughetti A, Marchetti P, Nuti M, Botticelli A, Napoletano C. Zizzari IG, et al. Among authors: rughetti a. J Pers Med. 2020 Nov 4;10(4):208. doi: 10.3390/jpm10040208. J Pers Med. 2020. PMID: 33158018 Free PMC article.
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Zizzari IG, Di Filippo A, Botticelli A, Strigari L, Pernazza A, Rullo E, Pignataro MG, Ugolini A, Scirocchi F, Di Pietro FR, Rossi E, Gelibter A, Schinzari G, D'Amati G, Rughetti A, Marchetti P, Nuti M, Napoletano C. Zizzari IG, et al. Among authors: rughetti a. Clin Cancer Res. 2022 Mar 1;28(5):1027-1037. doi: 10.1158/1078-0432.CCR-21-2918. Clin Cancer Res. 2022. PMID: 34980602 Free PMC article.
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Botticelli A, Cirillo A, Pomati G, Cortesi E, Rossi E, Schinzari G, Tortora G, Tomao S, Fiscon G, Farina L, Scagnoli S, Pisegna S, Ciurluini F, Chiavassa A, Amirhassankhani S, Ceccarelli F, Conti F, Di Filippo A, Zizzari IG, Napoletano C, Rughetti A, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: rughetti a. Cancer Immunol Immunother. 2023 Jul;72(7):2217-2231. doi: 10.1007/s00262-023-03384-9. Epub 2023 Mar 3. Cancer Immunol Immunother. 2023. PMID: 36869232 Free PMC article.
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. Zizzari IG, et al. Among authors: rughetti a. Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26. Cancer Immunol Res. 2018. PMID: 29700053
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.
Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, Strigari L, Tomao S, Cortesi E, Rughetti A, Marchetti P, Nuti M. Scirocchi F, et al. Among authors: rughetti a. EBioMedicine. 2022 May;79:104010. doi: 10.1016/j.ebiom.2022.104010. Epub 2022 Apr 25. EBioMedicine. 2022. PMID: 35477069 Free PMC article.
86 results